125033-59-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(Boc-aMinoMethyl)-3-hydroxypyrrolidine is used as a key building block for the synthesis of various pharmaceutical compounds. Its Boc-protected amino group and hydroxyl group provide unique chemical properties that facilitate the development of new drugs and pharmaceuticals with potential therapeutic applications.
Used in Organic Synthesis:
3-(Boc-aMinoMethyl)-3-hydroxypyrrolidine is used as a versatile intermediate in organic synthesis. The Boc group allows for selective reactions to occur at the hydroxyl group, while protecting the amine group from unwanted reactions. This feature makes it a valuable component in the synthesis of complex organic molecules with specific functional groups and properties.
Used in Drug Development:
3-(Boc-aMinoMethyl)-3-hydroxypyrrolidine has the potential to be utilized in the development of new drugs and pharmaceuticals. Its unique chemical properties and structure can be leveraged to design and synthesize novel drug candidates with improved efficacy, selectivity, and safety profiles. Researchers can explore its potential in various therapeutic areas, such as oncology, neurology, and infectious diseases, by incorporating it into the molecular frameworks of new drug candidates.

Upstream product

• 125033-36-5 3-aminomethyl-1-benzyl-3-hydroxypyrrolidine 
• 97266-84-7 5-benzyl-1-oxa-5-azaspiro[2.4]heptane 
• 872715-56-5 (+/-)-phenylmethyl 3-[({[(1,1-dimethylethyl)oxy]carbonyl}amino)methyl]-3-hydroxy-1-pyrrolidinecarboxylate 

Relevant academic research and scientific papers

N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

Quinolone- and naphthyridone carboxylic acid derivatives, process for their production, antibacterial compositions and feed additives containing them

An antibacterially active quinolone or naphthyridonecarboxylic acid derivative of the formula STR1 in which R1 stands for various organic radical, R2 stands for hydrogen, alkyl having 1 to 4 carbon atoms or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, R3 stands for hydrogen or amino, R4 stands for a radical of the formula STR2 A stands for N or C-R5, wherein R5 stands for hydrogen, halogen methyl, cyano or nitro or else together with R1 can form a bridge of the structure STR3 or a pharmaceutically utilizable hydrate, acid addition salt, alkali metal salt, alkaline earth metal salt, silver salt or guanidinium salt of the carboxylic acid when R2 is hydrogen.